Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) reported a third-quarter 2026 net loss of $53.9 million and provided updates on its gene-therapy trials. The loss widened from $45.8 million a year earlier. Cash, cash equivalents and available-for-sale securities totaled $348.9 million at September 30; Solid expects funding to last into H1 2028.
SGT-003 was generally well tolerated in 53 INSPIRE DUCHENNE participants as of November 3. A late-Q4 2026 FDA meeting will seek guidance on a potential accelerated approval pathway; Phase 3 IMPACT DUCHENNE dosing is ongoing. Five SGT-212 participants had no treatment-related serious adverse events as of November 3. Solid expects initial data in Q1 2027, subject to enrollment; the therapy received European Commission Orphan designation in October. SGT-501 trial screening has begun, with first dosing expected by year-end 2026 and initial safety data in H1 2027, subject to enrollment.
Solid Biosciences (SLDB) received European Commission Orphan designation for SGT-212, its investigational gene therapy for Friedreich’s ataxia.
The designation follows a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products. Five participants have received SGT-212 in the ongoing Phase 1b FALCON trial, with no treatment-related serious adverse events observed as of October 5, 2026. Solid expects to report initial clinical data in Q1 2027.
SGT-212 combines MRI-guided delivery to the brain’s dentate nuclei with intravenous delivery intended to reach the heart and other affected tissues. The approach is designed to deliver the full-length frataxin gene to affected tissues. SGT-212 also holds U.S. Food and Drug Administration Fast Track, Orphan Drug and Rare Pediatric Disease designations.
Solid Biosciences (SLDB) will present seven accepted research posters at the ESGCT Annual Congress on October 27–30, 2026, in Hamburg, Germany. The research covers its investigational SGT-003 gene therapy for Duchenne muscular dystrophy, the POLARIS-101 delivery platform and gene therapy manufacturing. Poster sessions are scheduled for October 28 and 29.
Solid Biosciences (Nasdaq: SLDB) granted 8,150 restricted stock units to one newly hired employee as an employment inducement.
The restricted stock units, or RSUs, vest in four equal installments on successive one-year anniversaries of the grant date, through the fourth anniversary. Each installment requires the employee’s continued service through its vesting date. The award was made under the 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (SLDB) will participate in three September 2026 investor conferences, featuring fireside chats with senior management that will be webcast live.
Events include the 2026 Cantor Global Healthcare Conference on September 9 at 3:55 p.m. ET, the 2026 Citi Biopharma Back to School Conference on September 10 at 3:00 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 1:00 p.m. ET. Live and replay webcasts for each session will be accessible for 90 days via the Events page in the Investors section of the company website.
Solid Biosciences (Nasdaq: SLDB) reported second quarter 2026 results and clinical updates. Cash, cash equivalents and available-for-sale securities were $377.7 million as of June 30, 2026, up from $187.9 million at year-end 2025, with a cash runway expected to extend into mid-2028, according to the company.
SGT-003 for Duchenne has been generally well tolerated in 53 participants in the Phase 1/2 INSPIRE DUCHENNE trial, and dosing has begun in the Phase 3 IMPACT DUCHENNE trial. Solid plans an FDA meeting in late Q4 2026 to seek guidance on a potential accelerated approval pathway. SGT-212 for Friedreich’s ataxia has shown no treatment-related serious adverse events in two dosed participants, with initial data expected in Q1 2027. SGT-501 for CPVT is in Phase 1b site-activation and screening, with first dosing targeted for 2H 2026. The company has executed 50+ agreements for its POLARIS-101™ capsid.
Q2 2026 R&D expenses were $44.3 million and G&A expenses $13.1 million, leading to a net loss of $54.8 million, compared with a $39.5 million net loss in Q2 2025.
Solid Biosciences (Nasdaq: SLDB) granted 6,580 restricted stock units (RSUs) to one newly hired employee under its 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments over four years, contingent on continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced it will participate in two upcoming investor conferences focused on healthcare.
President and CEO Bo Cumbo will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
Solid Biosciences (Nasdaq: SLDB) reported Q1 2026 results and pipeline progress. Cash, cash equivalents and securities were $380.7 million on March 31, 2026, with runway into H1 2028. Q1 2026 net loss was $56.7 million.
Key updates include first dosing in the Phase 3 IMPACT DUCHENNE trial for SGT-003, 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE, positive EMA Pediatric Investigation Plan opinion, and EU Orphan drug designation. SGT-212 dosed two participants with no serious adverse events, and ARTEMIS for SGT-501 is expected to begin dosing in H2 2026.
Solid Biosciences (Nasdaq: SLDB) dosed the first participant in its multi-country, randomized, placebo-controlled Phase 3 IMPACT DUCHENNE trial of SGT-003 on May 7, 2026. The program complements the Phase 1/2 INSPIRE trial where 46 participants have received SGT-003 and it has been generally well tolerated as of a May 4, 2026 cutoff.
The company received a positive EMA PIP opinion for pediatric development, holds FDA Fast Track, Rare Pediatric and Orphan Drug designations, and was awarded a UK Innovation Passport under ILAP.